Long-term effects of Olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients

Hypertension Research

Volumn 24, Issue 6, 2001, Pages 641-646

  Ichikawa, S ^a   Takayama, Y ^a  

^a Cardiovasc Hosp of Central Japan   (Japan)

Author keywords

Ang II receptor antagonist; Olmesartan; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; LOSARTAN; OLMESARTAN; RENIN;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERANCE; DYSPNEA; FEMALE; HUMAN; HYPERTENSION; MALE; PLASMA RENIN ACTIVITY; PREMEDICATION; PULSE RATE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TABLET;

ADULT; AGED; ALDOSTERONE; ANGIOTENSIN I; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PULSE; RECEPTORS, ANGIOTENSIN; RENIN; RENIN-ANGIOTENSIN SYSTEM; RESPIRATION DISORDERS; TETRAZOLES; TIME FACTORS;

EID: 0035210938     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.24.641     Document Type: Article

References (20)

1. Ang II receptor antagonists: An emerging new class of cardiovascular therapeutics
2. Pharmacology of CS-866, a novel nonpeptide Ang II receptor antagonist
3. Nonpeptide Ang II receptor antagonists: Synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position compounds
4. Clinical studies of CS-866, the newest angiotensin II receptor antagonist
5. Blood pressure and endocrine effects of single doses of CS-866, a novel Ang II antagonist, in salt-restricted hypertensive patients
6. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: Results from a 26-week, double-blind, multicentre study
7. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension
8. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension
9. Correlations among blood levels of renin-angiotensin-aldosterone, bradykinin, and catecholamines in healthy subjects
10. Risks of untreated and treated isolated systolic hypertension in the elderly: Meta-analysis of outcome trials
11. Pulse pressure as a risk factor for cardiovascular events in the MRC mild hypertension trial
12. Oral administration of DuP 753, a specific Ang II receptor antagonist, to normal male volunteers
13. Effects of losartan on blood pressure, PRA, and Ang II in volunteers
14. Characterization of the Ang II receptor antagonist TCV-116 in healthy volunteers
15. Candesartan cilexetil in hypertension: Effects of six weeks' treatment on haemodynamics, baroreceptor sensitivity and the renin-angiotensin-aldosterone system
16. Biochemical effects of losartan, a nonpeptide Ang II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients
17. Regulation of liver angiotensinogen and kidney renin mRNA levels by Ang II
18. Renin and angiotensinogen gene expression and intrarenal renin distribution during ACE inhibition
19. Differential kinetics of circulating Ang IV and II after treatment with Ang II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure
20. 2 receptor in hypertension